Table 3 Patient and disease characteristics (n=33)

From: Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed

Variable n (%)
Age (years), median (range) 67 (52–88)
65 years 67%
Karnofsky performance status
90–100 9 (27%)
80–70 19 (58%)
60 5 (15%)
PSA (ng ml−1), median (range) 33.4 (2.4–1060.0)
PSA DT (mo), median (range) 1.5 (0.1–7.0)
Measurable disease 11 (33%)
Disease sites
Bone 32 (97%)
LN 15 (45%)
Lung 7 (21%)
Liver 7 (21%)
Gleason score
8–10 27 (82%)
7 2 (6%)
NA 4 (12%)
Presence of pain 24 (73%)
Anaemia (Hb<13.5 g dl−1) 31 (94%)
LDH>ULN 12 (40%)a
Prior docetaxel dose (mg m−2)
Median (range) 518 (120–1500)
Number of patients progressed b
During last docetaxel treatment 24 (77%)
<3 mo since last docetaxel dose 26 (84%)
3 mo since last docetaxel dose 5 (16%)
Radiation
Curative 6 (18%)
Palliative 12 (36%)
Prior exposure to chemotherapy
Estramustine 11 (33%)
Etoposide 2 (6%)
Cyclophosphamide 2 (6%)
Mitoxantrone 4 (12%)
Docetaxel rechallenge 5 (15%)
Cabazitaxel 2 (6%)
Pattern of progression
PSA progression 32 (97%)
Bone scan progression 14 (42%)
RECIST progression 11 (33%)
Symptomatic progression 14 (42%)
  1. Abbreviations: DT=doubling time; LDH=lactate dehydrogenase; LN=lymph node; mo=months; PSA=prostate-specific antigen; ULN=upper limit of normal.
  2. aAvailable in 30 patients.
  3. bAvailable in 31 patients.